

Second Opinion: Integrating Novel Approaches into the Management of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following descriptions best applies to TAR-200?

- a. Internal radioactive implant
- b. Wafer-based chemotherapy implant
- c. Intravesical drug delivery system for gemcitabine

2. What is the regulatory status of TAR-200?

- a. Investigational
- b. FDA approved in combination with BCG for BCG-naïve non-muscle invasive bladder cancer (NMIBC)
- c. FDA approved for BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors

3. When is the administration vehicle of TAR-200 removed from the patient?

- a. Every week
- b. Every 3 weeks
- c. Every 3 months

4. Which of the following agents is an appropriate addition to front-line BCG for NMIBC according to Phase III clinical trial data?

- a. TROP2-targeting antibody-drug conjugate
- b. Immune checkpoint inhibitor
- c. FGFR3 inhibitor